CYB210010

From Wikipedia, the free encyclopedia
CYB210010
Identifiers
  • 2-[2,5-dimethoxy-4-(trifluoromethylsulfanyl)phenyl]ethanamine
PubChem CID
Chemical and physical data
FormulaC11H14F3NO2S
Molar mass281.29 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCN)OC)SC(F)(F)F
  • InChI=1S/C11H14F3NO2S/c1-16-8-6-10(18-11(12,13)14)9(17-2)5-7(8)3-4-15/h5-6H,3-4,15H2,1-2H3
  • Key:VOGDBAZLGHXJBS-UHFFFAOYSA-N

CYB210010 (2C-T-TFM) is a lesser-known psychedelic drug related to compounds such as 2C-T and 2C-T-21. Alexander Shulgin attempted to synthesise this compound in the 1990s, and mentions it in his book PiHKAL under the entry for 2C-T-21, but was unsuccessful in producing a key intermediate and never assigned it a 2C-T number. This compound was ultimately first synthesised by Geoffrey Varty and colleagues at Irish biopharmaceutical company Cybin in 2023. It has a Ki of 0.35 nM at 5-HT2A, and an EC50 of 4.1 nM at 5-HT2A and 7.3 nM at 5-HT2C, compared to 88 nM at 5-HT2B.[1] It is a potent, selective, long acting and orally active agonist for the 5-HT2A and 5-HT2C receptors and produces psychedelic-like responding in several different animal species.[2] It is not known to have been tested in humans.

See also[edit]

References[edit]

  1. ^ WO 2023156450, Nivorozhkin A, JA Hartsel, Canal CE, Salituro FG, Mueller TA, Greene BJ, Belser A, Avery KL, Reichelt AC, Varty GB, Palfreyman M, "Therapeutic phenethylamine compositions and methods of use", published 24 August 2023, assigned to Cybin Irl Limited 
  2. ^ Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, et al. (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". Journal of Medicinal Chemistry. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423.